Sanofi reports positive results from Phase II myelofibrosis trial
Patients with intermediate-2 or high-risk primary or secondary MF were involed in open label, randomised dose-ranging study that assessed the once-daily oral doses of 300mg, 400mg, and 500mg
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.